UNH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UnitedHealth Group Inc (UNH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has faced significant declines, the lack of positive trading signals, weak financial performance in Q4 2025, and cautious sentiment from Congress and analysts suggest that it is better to hold off on investing until clearer recovery signs emerge.
The technical indicators show a neutral trend. The MACD is positive and expanding, indicating mild bullish momentum. RSI is neutral at 52.779, and moving averages are converging, suggesting no strong directional movement. The stock is trading near its pivot level (284.418), with resistance at 293.379 and support at 275.456.
Billionaire Ole Andreas Halvorsen's investment in UnitedHealth indicates some confidence in the stock's recovery potential.
Defensive strategies recommend investing in healthcare stocks for stability, which could benefit UnitedHealth in the long term.
Significant stock price decline of 40% due to rising costs and a Medicare probe.
Analysts have lowered price targets across the board, citing disappointing Medicare Advantage rates and restructuring challenges.
Congress members have sold significant amounts of the stock recently, indicating cautious sentiment.
Weak financial performance in Q4 2025, with a 99.82% drop in net income and EPS.
In Q4 2025, UnitedHealth's revenue increased by 13.11% YoY to $113.2 billion. However, net income dropped by 99.82% YoY to $10 million, and EPS fell by 99.83% to $0.01. This indicates significant profitability challenges despite revenue growth.
Analysts have lowered their price targets significantly, with targets now ranging from $327 to $440. Most analysts maintain an Overweight or Buy rating, but the sentiment is cautious due to disappointing Medicare Advantage rates and restructuring challenges.
